Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2024 | Story Martinette Brits | Photo Stephen Collett
Dr Francois Jacobs
Dr Francois Jacobs received his Doctor of Philosophy degree in Chemistry on Monday, 9 December.

Dr Francois Jacobs, a 30-year-old PhD graduate, has recently returned from an intensive training workshop in Harwell, Oxford, courtesy of the David Blow Bursary. This prestigious award recognises outstanding African researchers making significant contributions to macromolecular crystallography.

Dr Jacobs earned his Doctor of Philosophy degree in Chemistry on Monday, 9 December. While earning a PhD by the age of 30 was not part of his initial plan, he always aspired to pursue higher education. “From a young age, I had a strong desire to study at university. Once I got there, my ambition shifted towards obtaining a PhD,” he says, reflecting on the journey that led to this remarkable achievement.

Groundbreaking research on cancer and antibiotics

Dr Jacobs’ research addresses some of the most pressing health challenges of our time: cancer and antibiotic resistance. Using crystallography, he investigates the interactions between newly developed anticancer and antibacterial compounds and biological structures such as proteins at the atomic level. This work is vital in combating the growing threat of antibiotic-resistant bacterial infections and advancing cancer treatments.

"For me, it's about seeing humans thrive and reducing the suffering caused by illness," he explains. "I lost my grandmother to cancer, and I hope my work can spare someone else’s loved one from a similar loss."

Prestigious workshop with global experts

The "DLS-CCP4 Data Collection and Structure Solution Workshop," hosted by Diamond Light Source, offered Dr Jacobs an unparalleled opportunity to learn from leading experts in macromolecular crystallography. The workshop covered critical skills such as growing protein and DNA crystals, preventing degradation during data collection, and processing complex data. Participants also gained insights directly from the engineers and scientists behind the facility’s cutting-edge software and synchrotron technology.

“It was an incredible opportunity to learn from some of the brightest minds in the field,” says Dr Jacobs. “Not only did I acquire new skills, but I also forged new collaborations with potential research partners who can help take my work to the next level.”

The David Blow Bursary, which enabled Dr Jacobs to attend this workshop, is awarded to  African researchers conducting impactful macromolecular crystallography studies.

"This training has been transformative," he adds. "It is a fantastic experience for any aspiring researcher, and I’m grateful to have had the chance to learn from these experts. Many researchers who attend workshops like this go on to work at the Diamond Light Source itself. I am eager to see where this training will take me."

A vision for the future

As Dr Jacobs continues his research, he remains driven by the hope that his work will lead to life-saving advancements in healthcare. “I want my research to provide hope and solutions for individuals battling cancer and bacterial infections,” he says.

His achievements exemplify the transformative power of education, research, and collaboration, and his story serves as an inspiration to aspiring researchers across Africa. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept